The UK and US have reached a major bilateral deal that will guarantee zero duties on UK medicine products being sold in the American market.
The Terms of the Accord
As part of the deal, the UK has committed to boost funding on drugs through the National Health Service (NHS). This pledge secures that duties on these vital goods will stay at nothing for a duration of three years.
This deal comes after recent threats to hike duties on patented drug imports, with potential rates discussed up to one hundred percent.
"This arrangement with the Britain reinforces the worldwide climate for cutting-edge drugs and introduces much-needed balance to transatlantic medicine commerce," a statement said.
Trade Significance
Pharmaceuticals constitute one of the Britain's most significant export categories to the United States, which is clearly the primary market for major British pharmaceutical firms.
Export figures reveal that in the 12 months leading up to September, the UK shipped drugs totaling £11.1bn to the US. This figure accounted for nearly one-fifth of total UK exports in that span.
"This guarantee safeguards jobs, boosts capital expenditure and facilitates the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary commented.
Specific NHS Changes
The agreement includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new medicines to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to raise overall health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to prevent overspending will be restricted at 15%. Previously, rebates were more than twenty percent.
Industry Background
This agreement follows a ongoing row between the sector and the ministers over drug pricing and approval rates.
This friction were heightened by arguments that US patients were paying several times more for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or scrapped, while major expansions have been announced toward US facilities.
One official publicly accepted that the NHS needed to spend more on drugs, noting that its spending on drugs had decreased as a percentage of its resources over the past decade.
